into shares of our common stock at the public offering price of the Class A Units, together with the equivalent number of Warrants
A convertible preferred stock and upon exercise of the Warrants, collectively, as the securities.Assuming we sell all 10,588,235 Class A Units  being offered in this offering at a public offering price of $0.
price of our common stock on The NASDAQ Capital Market on November 21 , 2016, and all 3,000 Class B Units being offered
comply with certain reduced public company reporting requirements for this prospectus and future filings.Per Class AUnitPer Class BUnitTotalPublic offering price(1)$$1,000$Placement agent fees(2)$$$Proceeds, before expenses, to us$$$(1)The public offering price is $          per
2016TABLE OF CONTENTSPageProspectus Summary1Risk Factors8Special Note Regarding Forward-Looking Statements11Use of Proceeds13Price Range of Our Common Stock14Dividend Policy15Capitalization16Business17Management51Certain Relationships and Related Party Transactions56Principal Stockholders65Description of Capital Stock69Description of Securities We Are Offering73Plan of Distribution75Legal Matters76Experts76Where You Can Find Additional Information76Incorporation of Certain Information By Reference77iTable of ContentsWe have not, and the placement
and loss of investment by our stockholders.·We are dependent on the success of our INOpulse product candidates and our ability to develop, obtain marketing approval for
business could be materially harmed.·We rely on Ikaria, as our single source supplier, for our supply of nitric oxide for the clinical trials of INOpulse.
to maintain or enforce the underlying patents, our competitive position and market share will be harmed.·We may seek to enter into collaborations with third parties for the development and commercialization of our product candidates.
and Warrants to purchase 10,588,235 shares of our common stock underlying the Class A Units .Class B Units offered by usWe are also offering to those purchasers, if any, whose purchase of Class A Units in this offering would otherwise result in the purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% of our outstanding common stock immediately following the consummation of this offering, the opportunity, in lieu of purchasing Class A Units, to purchase Class B Units.
Each Class B Unit will consist of one share of our Series A convertible preferred stock, with a stated value of $1,000 and convertible into shares of our common stock at the public offering price of the Class A Units, together with the equivalent number of Warrants as would have been issued to such purchaser if they had purchased Class A Units based on the public offering price.Ownership of the Class B Units alone will not increase the
any such     affiliate, would beneficially own more than 4.99% of the total number of shares of our outstanding common stock.However, any holder may decrease or increase such ownership percentage to any other percentage, provided that any increase in such percentage shall not be effective until 61 days after such notice to us.
Exceeding 4.99% ownership in shares of our outstanding common stock will trigger certain SEC filing requirements by such holder, including the submission of a Schedule 13G or Schedule 13D, as applicable, while such ownership percentage remains above 4.99%.Shares of Series A convertible preferred stock do not generally
underlying the Class B Units.WarrantsEach Warrant included in the units will have an exercise price per full share of common stock equal to 100% of the public offering price of the Class A Units, will be immediately exercisable and will expire five years from the date on which such Warrants become exercisable.There is no established public trading market for the warrants,
of $0.85, the reported closing price of our common stock on The NASDAQ Capital Market on November 21, 2016) and assumes none of the warrants issued in this
offering are exercised).5Table of ContentsUse of proceedsWe intend to use the net proceeds from this offering for general corporate purposes, including manufacturing expenses, clinical trial expenses, research and development expenses and general and administrative expenses.
There is no established public trading market for the Series A convertible preferred stock or the Warrants to be issued in this offering, and we do not intend to apply to list such securities on any securities exchange or automated quotation system.The number of shares of
price of our common stock and the value of the warrants to decline, resulting in a loss of all or part of your investment.Risks Related to this OfferingThere is no public market for the Series
Our future funding requirements will depend on many factors, including:·the costs and timing of our research and development activities;·the progress and cost of our clinical trials and other research and development activities;·the cost and timing of securing manufacturing capabilities for our clinical product candidates
from this offering for general corporate purposes, including manufacturing expenses, clinical trial expenses, research and development
table sets forth the ranges of high and low sales prices per share of our common stock as quoted on the NASDAQ Global Market.HighLowYear Ended December 31, 2015First Quarter (beginning February 13, 2015)$12.92$8.01Second Quarter$10.88$7.32Third Quarter$8.54$2.75Fourth Quarter$5.09$2.47Year Ending December 31, 2016First Quarter$3.75$1.90Second Quarter$4.58$1.09Third Quarter$2.68$1.24Fourth Quarter (through November 21 , 2016)$1.48$0.85As of November 21 , 2016, there were
Use of inhaled nitric oxide is approved by the U.S. Food and Drug Administration, or the FDA, and certain other regulatory authorities to treat persistent PH of the newborn.
has marketed continuous-flow inhaled nitric oxide as INOmax for hospital use in this indication since FDA approval in 1999.
investigational new drug applications, or INDs, for INOpulse for the treatment of patients with PAH and PH-COPD.
certification covers the design, development and manufacture of inhaled pulsatile nitric oxide drug delivery systems including
in the use of inhaled nitric oxide in treating PH and in the development of drug-device combination product candidates.
the United States each year, indicating that physicians already use nitric oxide in some PAH patients.
requiring close clinical management, special handling and distribution through specialty pharmacies.Scientific Rationale for Use of INOpulse for PH-COPDThe mechanism of action of inhaled nitric oxide
that early pulsed delivery of nitric oxide could be directed specifically to the well-ventilated alveoli.Clinical Development ProgramINOpulse for PH-COPD is designated as a drug-device
Practices, or cGMP, is the only FDA-approved site for manufacturing medical nitric oxide in the world.To support business outside of the United States,
the regulatory period during which the FDA cannot approve another application.Patent Term Restoration and ExtensionA patent claiming a new drug product or medical
stock to another person or enter into any other similar business combination transaction, or effect a liquidation;·authorize, issue, sell, offer for sale or solicit offers to buy any shares of our common stock or any convertible securities
table sets forth the aggregate number of shares of our common stock that these directors, executive officers and 5% stockholders
Weinstein(8)4,859,88533.3%All executive officers and directors as a group (14 persons)7,199,37649.3%25.1%65Table of Contents*Less than one percent.(1)Based on information provided in a Schedule 13G filed by New Mountain Investments II, LLC on February 16, 2016, consists of